Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 565 pages

Showing 151 - 200


breast cancer

Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in Triple-Negative Breast Cancer

An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effects...

breast cancer

Association of Bisphosphonate Use and Breast Cancer Risk in Postmenopausal Women

A study in postmenopausal women in the French E3N prospective cohort indicated bisphosphonate use was not associated with a reduced risk of breast cancer. These findings were reported by Fournier et al in the Journal of Clinical Oncology. Study Details The study included 64,438 postmenopausal...

breast cancer

Breast Cancer Survivor Preferences for Providers of Aspects of Primary Care After Cancer Treatment

In a study reported in the Journal of Clinical Oncology, Wallner et al found that minority women vs white women and women with a lower vs higher attained education level were more likely to prefer oncology-directed care vs primary care provider–directed care for aspects of care normally...

breast cancer

Genetic Study Identifies Susceptibility Loci Modifying Risk for Breast Cancer After Radiation Therapy for Childhood Cancer

As reported in the Journal of the National Cancer Institute, Morton et al have identified gene loci associated with radiation-related risk of breast cancer in survivors of childhood cancer. Study Details The study was a genome-wide association study of breast cancer in female survivors of...

breast cancer

Neoadjuvant Ado-trastuzumab Emtansine vs Trastuzumab in Early HER2-Positive, HR-Positive Breast Cancer

A West German Study Group phase II trial, reported by Harbeck et al in the Journal of Clinical Oncology, has shown a higher pathologic complete response rate with neoadjuvant ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) with or without endocrine therapy vs trastuzumab (Herceptin)...

breast cancer

MammaPrint Scoring and Indolent Node-Negative Breast Cancer

In an analysis reported in JAMA Oncology, Esserman et al found that an ultralow-risk designation using the 70-gene MammaPrint assay is capable of identifying patients with node-negative disease who have a very low long-term risk of death from breast cancer after surgery without systemic therapy....

breast cancer

Anthracycline-Free Adjuvant Treatment in Early TOP2A-Normal Breast Cancer

The Danish phase III DBCG 07-READ trial has shown no difference in disease-free survival with adjuvant docetaxel/cyclophosphamide vs epirubicin, cyclophosphamide, and docetaxel in patients with early TOP2A-normal breast cancer. These trial results were reported in the Journal of Clinical Oncology...

breast cancer

Effect of Patient-Reported Symptoms on Adherence to Preventive Treatment for Breast Cancer

In an analysis of the UK cohort of the International Breast Cancer Intervention Study (IBIS-I) reported in the Journal of Clinical Oncology, Smith et al found similar effects of predefined symptoms on nonadherence in both tamoxifen and placebo recipients. IBIS-I randomized women at high risk of...

breast cancer

Interventionist-Guided Weight Loss Program for African American Breast Cancer Survivors

As reported by Stolley et al in the Journal of Clinical Oncology, a community-based interventionist-guided weight loss program for African American breast cancer survivors (Moving Forward) proved successful in achieving weight loss goals compared with a self-guided weight loss program. African...

breast cancer

Study Estimates Risks of Breast and Ovarian Cancers in BRCA1/2-Mutation Carriers

In a prospective cohort study reported in JAMA, Kuchenbaecker et al derived estimates of cumulative risks for breast, ovarian, and contralateral breast cancers among women carrying BRCA1 or BRCA2 mutations. Study Details The study involved data from 6,036 BRCA1 and 3,820 BRCA2 carriers recruited...

breast cancer

Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Adjuvant Therapy for Breast Cancer

The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by...

breast cancer

Equivalence Trial of Neoadjuvant Trastuzumab Biosimilar CT-P6 vs Trastuzumab in HER2-Positive Breast Cancer

A phase III equivalence trial has shown comparable pathologic complete response rates with the proposed trastuzumab biosimilar CT-P6 vs reference trastuzumab (Herceptin) in neoadjuvant treatment of HER2-positive early breast cancer. The study was reported by Stebbing et al in The Lancet Oncology....

breast cancer

Trends in Surgery After Initial Lumpectomy for Breast Cancer

In a study reported in JAMA Oncology, Morrow et al found that the rates of surgery after initial lumpectomy for stage I or II breast cancer have decreased with dissemination of guidelines advocating a minimal negative surgical margin. A 2014 consensus statement of the Society of Surgical Oncology...

breast cancer

Combination of Buparlisib and Fulvestrant in Postmenopausal Women With Advanced Breast Cancer

In the phase III BELLE-2 trial, the addition of the PI3K inhibitor buparlisib to fulvestrant (Faslodex) improved progression-free survival in postmenopausal hormone receptor–positive, HER2-negative advanced breast cancer—but at the cost of excessive toxicity. Results were reported in...

breast cancer

Adding Abemaciclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

In the phase III MONARCH 2 trial reported at the recent ASCO Annual Meeting and in the Journal of Clinical Oncology by Sledge et al, the addition of the selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib to fulvestrant (Faslodex) improved progression-free survival in hormone...

breast cancer

OlympiAD Trial: Olaparib in Metastatic Breast Cancer With Germline BRCA Mutation

As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Robson et al, the phase III OlympiAD trial showed that the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) prolonged progression-free survival vs standard therapy in...

breast cancer

Breast Cancer Risk and Histologic Findings in Serial Benign Biopsies

As reported by Visscher et al in the Journal of the National Cancer Institute, changes in the histologic category between initial and subsequent biopsies had a significant effect on the risk for breast cancer among women with serial benign biopsy findings. Study Details The study involved 1,414...

breast cancer

Final Overall Survival Results of TH3RESA Trial in Breast Cancer

The final overall survival results of the phase III TH3RESA trial indicate a 32% reduction in risk of death with ado-trastuzumab emtansine (Kadcyla) vs treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer. The findings were reported in The ...

breast cancer

Tai Chi Chih vs Cognitive Behavioral Therapy for Insomnia in Breast Cancer Survivors

In a study reported in the Journal of Clinical Oncology by Irwin et al, Tai Chi Chih, a form of movement meditation, was noninferior to insomnia-specific cognitive behavioral therapy in improving insomnia in breast cancer survivors. Study Details In the study, 90 patients with insomnia from the...

breast cancer

Effect of Fixed Second Appointments on Breast Cancer Screening Attendance

In a UK study reported in The Lancet Oncology, Allgood et al found that provision of a second timed appointment for breast cancer screening improved screening rates among women who did not attend a first offered appointment. Study Details In the study, women who were invited for breast screening...

breast cancer

Final Overall Survival Results of EMILIA Trial in Breast Cancer

As reported in The Lancet Oncology by Diéras et al, the final overall survival results of the phase III EMILIA trial show improved outcome with ado-trastuzumab emtansine (Kadcyla) vs capecitabine plus lapatinib (Tykerb) in previously treated HER2-positive advanced breast cancer. Approval of...

breast cancer

Long-Term Follow-up of Intergroup Exemestane Study

A final efficacy analysis of the Intergroup Exemestane Study, reported in the Journal of Clinical Oncology by Morden et al, shows continued benefit of switching to adjuvant exemestane after 2 to 3 years of tamoxifen in patients with early breast cancer. Study Details In the trial, patients who...

breast cancer

Hypofractionated Postmastectomy Radiation in Breast Cancer

In a phase II trial, Khan et al found that hypofractionated postmastectomy radiotherapy, completed in 15 treatment days, was safe and effective in women with stage II to IIIa breast cancer. The study was reported in the Journal of Clinical Oncology. Study Details In the study, 67 women from 2...

breast cancer

Changes in HER2 Breast Cancer Testing According to 2007 and 2013 ASCO/CAP Guidelines

Hanna et al have reported that the 2013 update to the 2007 ASCO/College of American Pathologists (CAP) recommendations for HER2 testing in breast cancer did not result in changes in the overall HER2-positivity rate but was associated with a higher rate of equivocal results. Their findings were...

breast cancer

Adding Pertuzumab to Trastuzumab/Capecitabine in Pretreated HER2-Positive Metastatic Breast Cancer

The phase III PHEREXA trial has shown no significant improvement in progression-free survival with the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine in patients with HER2-positive metastatic breast cancer with disease progression during or after trastuzumab-based...

breast cancer

Final, 10-Year Follow-up of Phase III Trial on Adding Gemcitabine to Adjuvant Therapy in Breast Cancer

The final, 10-year follow-up of the ‘all comers’ tAnGo trial, reported by Earl et al in The Lancet Oncology, continued to show no overall benefit of adding gemcitabine to adjuvant therapy in women with early-stage breast cancer. The trial, initiated in 2001, included patients...

breast cancer

Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology by Kurian et al, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics counselor and that many with BRCA1/2 variants of uncertain significance...

breast cancer

Benefit of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors

A randomized trial, reported by Maly et al in the Journal of Clinical Oncology, has shown that having an individualized survivorship care plan in place was associated with increased physician implementation of recommended breast cancer survivorship care among low-income, predominantly Latina breast ...

breast cancer

Efficacy Analysis of ABC Breast Cancer Trials of Adjuvant Taxane With/Without Anthracycline in HER2-Negative Disease

As reported by Blum et al in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens vs six cycles of...

breast cancer

Effect of Radiotherapy Boost for Ductal Carcinoma in Situ After Whole-Breast Radiotherapy

In an analysis reported in JAMA Oncology, Moran et al found that a radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy was associated with a reduction in the risk for ipsilateral breast tumor recurrence. Study Details The analysis pooled...

breast cancer

Satisfaction With Surgical Decision-Making in Women Considering Contralateral Prophylactic Mastectomy for Breast Cancer

In a study reported in JAMA Surgery, Katz et al found that most patients considering contralateral prophylactic mastectomy for stage 0 to II breast cancer were satisfied with surgical decision-making. Most surgeons discussed contralateral prophylactic mastectomy and most did not recommend against...

breast cancer

Patient-Reported Outcomes With Immediate Implant-Based or Autologous Breast Reconstruction

As reported in the Journal of Clinical Oncology by Pusic et al, patient-reported outcomes in the Mastectomy Reconstruction Outcomes Consortium Study indicate that autologous tissue breast reconstruction is associated with greater breast satisfaction and greater sexual and psychosocial well-being...

breast cancer

Anti–Trop-2 Antibody Drug Conjugate in Heavily Pretreated Metastatic Triple-Negative Breast Cancer

As reported in the Journal of Clinical Oncology by Bardia et al, the anti–Trop-2 antibody drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily pretreated metastatic triple-negative breast cancer. Trop-2, a glycoprotein initially identified ...

breast cancer

Effect of Polypharmacy on Adherence to Adjuvant Endocrine Therapy for Breast Cancer

In a retrospective cohort study reported in the Journal of Oncology Practice, Calip et al found that polypharmacy overall was associated with increased adherence to adjuvant endocrine therapy for breast cancer. However, frequent use of some medication classes was associated with decreased...

breast cancer

Impact of 70-Gene Signature on Adjuvant Chemotherapy Decisions in Breast Cancer

In a Dutch observational study reported in the Journal of Clinical Oncology, Kuijer et al found that use of the MammaPrint 70-gene signature (70-GS) test changed physician-intended recommendations to administer adjuvant chemotherapy in half of patients with early-stage estrogen...

breast cancer

Suboptimal BMD Evaluation in Postmenopausal Women With Early-Stage Breast Cancer Receiving Aromatase Inhibitors

In a study reported in the Journal of Oncology Practice, Stratton et al found that most postmenopausal Medicare patients with early-stage breast cancer receiving aromatase inhibitor therapy do not receive recommended bone mineral density (BMD) measurements. Most expert panels recommend BMD...

breast cancer

Association of Metformin Use for Diabetes With Outcomes in HER2-Positive Breast Cancer

In an analysis from the phase III ALTTO trial reported in the Journal of Clinical Oncology, Sonnenblick et al found that among patients receiving adjuvant therapy for HER2-positive breast cancer, those with diabetes who received metformin had better outcomes than those who did not receive...

breast cancer

Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

As reported in the Journal of Clinical Oncology by Dhesy-Thind, ofJuravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer. The...

breast cancer

Dutch Study Examines Effect of Internet-Based Cognitive Behavioral Therapy on Sexual Functioning in Breast Cancer Survivors

In a Dutch study reported in the Journal of Clinical Oncology, Hummel et al found that use of an Internet-based cognitive behavioral therapy intervention improved sexual functioning among breast cancer survivors. Study Details In the study, 169 women with a diagnosis of sexual dysfunction from 10 ...

breast cancer

Neoadjuvant Dual HER2 Blockade in HER2-Enriched Early Breast Cancer

In the Spanish phase II PAMELA study reported in The Lancet Oncology, Llombart-Cussac et al found that the HER2-enriched subtype was associated with the highest likelihood of pathologic complete response after neoadjuvant trastuzumab (Herceptin) and lapatinib (Tykerb) without chemotherapy in...

breast cancer

Effect of Scalp Cooling on Hair Loss in Women Receiving Nonanthracycline Chemotherapy for Breast Cancer

In a prospective cohort study reported in JAMA, Rugo et al found that use of a scalp-cooling device reduced hair loss in women receiving nonanthracycline chemotherapy for early-stage breast cancer. Study Details In the study, 101 evaluable patients from 5 U.S. centers with stage I or II breast...

breast cancer

11-Year Follow-up of Adjuvant Trastuzumab in the HERA Trial

In the 11-year follow-up of the HERA trial reported in The Lancet, Cameron et al found that 1 year of trastuzumab (Herceptin) following adjuvant therapy for HER2-positive breast cancer remained associated with improved disease-free and overall survival compared with observation. No additional...

breast cancer

Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial

In a study reported in the Journal of Clinical Oncology, Borgquist et al found that use of cholesterol-lowering medication during adjuvant endocrine therapy was associated with a reduced risk of breast cancer recurrence in hormone receptor–positive women in the BIG 1-98 trial. Study Details ...

breast cancer

Chinese Trial Adds Utidelone to Capecitabine in Heavily Pretreated Patients With Metastatic Breast Cancer

In a Chinese phase III trial reported in The Lancet Oncology, Zhang et al found that adding the epothilone analog utidelone to capecitabine prolonged progression-free survival in women with heavily pretreated metastatic breast cancer refractory to both anthracycline and taxane treatment. Study...

breast cancer

Study Finds Suboptimal Use of Adjuvant Endocrine Therapy in Breast Cancer

In a retrospective cohort study reported in JAMA Oncology, Daly et al found that recommended use of adjuvant endocrine therapy for breast cancer improved in the United States between 2004 and 2013 but remains suboptimal. The study included data on 981,729 women with stage I to III breast cancer...

breast cancer

Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer

An interim analysis of the SCALP trial, reported in JAMA by Nangia et al, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling. The study was stopped early on the basis of efficacy....

breast cancer

Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer

In a population-based study reported in a research letter in JAMA, Kurian et al found that genetic testing and genetic counseling are suboptimal among women with newly diagnosed breast cancer. Study Details The study involved 2,451 women aged 20 through 79 years diagnosed with stage 0 to II...

breast cancer

Zoledronic Acid Every 12 Weeks vs Every 4 Weeks in Women With Breast Cancer and Bone Metastases

In the phase III OPTIMIZE-2 trial reported in JAMA Oncology, Hortobagyi et al found that an every-12-week schedule of zoledronic acid was noninferior to an every-4-week schedule in terms of skeletal-related event rate in women with bone metastases from breast cancer who were currently receiving...

breast cancer

Residual Cancer Burden, Breast Cancer Phenotype, and Long-Term Prognosis After Neoadjuvant Chemotherapy

In a study reported in the Journal of Clinical Oncology, Symmans et al found that residual cancer burden (RCB) after neoadjuvant chemotherapy was significantly prognostic for long-term outcome across breast cancer subtypes. Study Details The study included 5 patient cohorts from The University of ...

breast cancer

Accelerated Partial-Breast vs Whole-Breast Irradiation After Breast-Conserving Surgery

As reported in The Lancet Oncology by Polgár et al, 5-year late side effects and cosmetic results were similar with accelerated partial-breast irradiation (APBI) with interstitial brachytherapy vs whole-breast irradiation (WBI) after breast-conserving surgery for low-risk invasive and in...

Advertisement

Advertisement



;
Advertisement